ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 786

Anti-Carbamylated Protein Antibodies Identify Systemic Lupus Erythematosus Patients with Erosive Arthritis: Analysis of a Regional Swedish Register

Alf Kastbom1, Philip Wallin2, Michael Ziegelasch1, Thomas Skogh1, Leendert Trouw3 and Christopher Sjöwall1, 1Department of Clinical and Experimental Medicine, Rheumatology/AIR, Linköping, Sweden, 2Linköping University, Clinical and Experimental Medicine, Sweden, Rheumatology/AIR, Linköping, Sweden, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: ACPA, Arthritis, radiology and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Articular manifestations affect a majority of patients with systemic lupus erythematosus (SLE), at least at some time during the disease course. Several investigators have estimated the frequency of erosive arthritis in SLE to about 5%. Detection of antibodies to ‘cyclic citrullinated peptide’ (anti-CCP) is an important diagnostic and prognostic tool in arthritis, since it is highly specific for rheumatoid arthritis (RA) and predictive of erosive disease. While anti-CCP reactivity in RA is citrulline-dependent, it has been suggested that anti-CCP in SLE is generally not, and thus also reacts with the corresponding ‘cyclic arginine peptide’ (CAP). Recently, it has been shown that antibodies targeting carbamylated proteins (anti-CarP) may occur in anti-CCP/rheumatoid factor negative cases even before the onset of RA. We analyzed anti-CCP, anti-CAP and anti-CarP in sera from patients in our well-characterized regional SLE register and related the findings to X-ray data, physical function and smoking habits.

Methods:

We included 236 patients (88% women) in the ‘Clinical Lupus Register in Northeastern Gothia’. 212 had established disease, whereas the remaining 24 had recent-onset SLE at the timepoint of blood sampling. 75% met the ACR criterion for arthritis. Cases were classified as SLE according to any of the following criteria sets: the 1982 American College of Rheumatology criteria (84%) or the 2012 Systemic Lupus International Collaborating Clinics (SLICC-12) criteria (99%). IgG anti-CCP and anti-CAP ELISA kits (Euro-Diagnostica) were used. IgG anti-CarP was quantified with ELISA as previously described. X-ray data (hands, wrists and/or feet) were available in medical records of 91 cases (39%).

Results:

16 patients (6.8%), all meeting SLICC-12, were anti-CCP positive, 9 of whom were also anti-CAP positive. 4 of the 7 patients with citrulline-dependent anti-CCP had a history of biopsy-proven nephritis. 23 patients (9.7%), all meeting SLICC-12, were anti-CarP positive. Only 6 of the anti-CarP positive cases were identified as anti-CCP positive. Neither anti-CCP nor anti-CarP were associated with arthritis judged by physical examination, nor to any other SLE phenotype. The presence of anti-CarP was associated with a positive lupus anticoagulant test (Fisher’s exact test, p=0.019). Smoking habits and HAQ did not associate with any of the antibodies. X-ray-proven erosions were found in 10 patients (4.2%) and were significantly associated with anti-CarP (Fisher’s exact test, p=0.025), whereas the association with anti-CCP did not reach statistical significance (Fisher’s exact test, p=0.07).

Conclusion:

Erosive arthritis is uncommon in SLE and our findings are in line with previous observations reporting a prevalence of 4-5%. Anti-CarP antibodies have previously not been studied in SLE. Herein, we demonstrate that anti-CarP in SLE: (1) is more frequently found than anti-CCP; (2) mainly identifies a different subgroup of cases compared with anti-CCP; and (3) associates significantly with erosive disease.


Disclosure: A. Kastbom, None; P. Wallin, None; M. Ziegelasch, None; T. Skogh, None; L. Trouw, None; C. Sjöwall, None.

To cite this abstract in AMA style:

Kastbom A, Wallin P, Ziegelasch M, Skogh T, Trouw L, Sjöwall C. Anti-Carbamylated Protein Antibodies Identify Systemic Lupus Erythematosus Patients with Erosive Arthritis: Analysis of a Regional Swedish Register [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/anti-carbamylated-protein-antibodies-identify-systemic-lupus-erythematosus-patients-with-erosive-arthritis-analysis-of-a-regional-swedish-register/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-carbamylated-protein-antibodies-identify-systemic-lupus-erythematosus-patients-with-erosive-arthritis-analysis-of-a-regional-swedish-register/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology